Scoop: After not making 2009's list, Roche came back in force, laying off 4,800 workers in one fell swoop this November. Those cuts will take place over the next two years, along with another 800 transfers in-company and 700 to third parties. According to the company's release, 2,650 of those cuts will come from sales and marketing. The company cited taspoglutide's poor results as one of the factors in the layoffs.
"This is a comprehensive, focused initiative to reinforce Roche's long-term innovation capability in the face of increased price pressures and a more challenging market environment. We will continue to drive our highly promising product pipeline to help seriously ill patients and contribute to more efficient healthcare systems," Roche CEO Severin Schwan (photo) said in a statement. The cuts should save Roche $2.7 billion through 2012, and another $2.4 billion after 2012.